Le Lézard
Classified in: Health, Covid-19 virus
Subject: ATY

Investors in QuidelOrtho Corporation f/k/a Quidel Corporation Should Contact The Gross Law Firm Before June 11, 2024 to Discuss Your Rights - QDEL


NEW YORK, May 10, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of QuidelOrtho Corporation f/k/a Quidel Corporation (NASDAQ: QDEL).

Shareholders who purchased shares of QDEL during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.

CONTACT US HERE:

https://securitiesclasslaw.com/securities/quidelortho-loss-submission-form/?id=78980&from=4

CLASS PERIOD: February 18, 2022 to April 1, 2024

ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (a) that QuidelOrtho sold more COVID-19 tests to its distributors and pharmacy chain customers than they could resell to healthcare providers and end customers; (b) that excess inventories of COVID-19 tests existed throughout the supply chain; (c) that, as a result of (a)-(b) above, QuidelOrtho's distributors and pharmacy chain customers were poised to significantly reduce their COVID-19 test orders; (d) that undisclosed problems created a heightened risk that the new test called the savanna respiratory viral panel-4 test would experience a delayed commercial launch in the united states; (e) that, as a result of (a)-(d) above, defendants lacked a reasonable basis for their positive statements about QuidelOrtho's business, financials, and growth trajectory.

DEADLINE: June 11, 2024 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/quidelortho-loss-submission-form/?id=78980&from=4

NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of QDEL during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is June 11, 2024. There is no cost or obligation to you to participate in this case.

WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: [email protected]
Phone: (646) 453-8903

SOURCE The Gross Law Firm


These press releases may also interest you

at 13:53
The Bluffs Addiction Campuses has officially expanded its specialized treatment program, Your Six Recovery (Y6R), dedicated to serving veterans and struggling with addiction and mental health disorders. The ribbon-cutting ceremony on May 13...

at 13:45
The American Academy of Orthopaedic Surgeons (AAOS) announced a formal collaboration with Blue Cross and Blue Shield Association (BCBSA) to allow consenting participants' quality outcomes data from the American Joint Replacement Registry (AJRR) to be...

at 13:16
CAQH is pleased to announce the appointment of Chris Schaefer as the new Chief Financial Officer. Chris will also serve as a member of the Executive Leadership Team. In his new role, Chris will be responsible for directing the organization's...

at 13:15
"I wanted to create a new set of smart support bands to monitor a person's movements and muscle expansion/contraction during exercise workouts, athletic training, or simply everyday activities," said an inventor, from Hueytown, Ala., "so I invented...

at 13:12
Today, Terragnosis Inc., a Canadian drug development company, announced IBEX011, the first GMP extract of Tabernanthe iboga available for use in ibogaine clinics and academic research. IBEX011 also marks the first time that an ibogaine product is...

at 13:00
The American Academy of Pediatric Dentistry (AAPD), the leading authority on children's oral health, will celebrate the 2024 winners of its prestigious awards during the organization's Annual Meeting, AAPD 2024, in Toronto from May 24-26....



News published on and distributed by: